trans-trismethoxy Resveratrol

trans-trismethoxy Resveratrol (CAS No.: 22255-22-7) is a naturally derived stilbene analog of resveratrol, classified within polyketide synthase-derived compounds, and is widely investigated in biomedical research for its anti-angiogenic, anti-inflammatory, and anticancer properties. Functionally, it modulates key signaling pathways and enzymatic activities involved in cell proliferation and survival, including inhibition of VEGFR2-mediated angiogenic signaling, suppression of TNF-α-induced NF-κB activation, and disruption of microtubule dynamics through tubulin depolymerization, collectively contributing to cell cycle arrest, apoptosis induction, and reduced metastatic potential. In vitro studies indicate that its cytotoxic activity varies across cancer cell models, exhibiting effects in the low micromolar range in several tumor cell lines such as prostate, colon, and leukemia cells, while showing comparatively weaker cytotoxicity in certain breast and liver cancer models, suggesting context-dependent efficacy. In vivo and organismal studies, including zebrafish embryo assays, demonstrate pronounced anti-angiogenic activity and selective endothelial cell toxicity, supporting its relevance in vascular biology research. This compound is commonly utilized in studies focused on tumor angiogenesis, inflammatory signaling, and cytoskeletal regulation, with experimental concentrations and dosing regimens adjusted according to specific cellular systems, disease models, and research objectives in drug discovery and mechanistic investigations.